Psychedelics Archives - Page 30 of 68

2 minute read

Atai Life Sciences Q1 2023 Results, Pipeline Update On DMT And Psilocybin Clinical Trials

May 11, 2:11 PM

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) reported the financial results for its first quarter ended March 31, 2023, and provided the period’s business highlights. Consolidated quarterly financials:

ATAI

1 minute read

Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed

By Lara Goldstein

May 10, 4:23 PM

FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first cohort of participants on its

HUGE

1 minute read

Stress-Related Mood Disorders And Alzheimer’s: Can This Patented Ketamine Drug Help?

By Lara Goldstein

May 10, 11:15 AM

Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and development.

SILO

1 minute read

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

By Lara Goldstein

May 9, 6:29 PM

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.

CYBN

3 minute read

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More

By Lara Goldstein

May 8, 4:23 PM

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

CMND

2 minute read

Phase 2 Psilocybin Therapy Trial For Patients With Treatment-Resistant PTSD: Latest Findings

By Lara Goldstein

May 7, 11:52 AM

Cannabis company Creso Pharma (OTCMKTS: COPHF)’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc.

COPHF

2 minute read

MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections

By Lara Goldstein

May 5, 2:20 PM

Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business highlights. Numbers show:

MNMD

2 minute read

Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation

By Maureen Meehan

May 5, 10:55 AM

GBB Drink Lab, which makes the world’s first formulated drink that aids in rapid blood alcohol detoxification - a handy tool, has filed a lawsuit against the psychedelics biotech company FSD Pharma (NASDAQ: HUGE).

HUGE

1 minute read

Incannex Stock Trading Higher On Entering A Lease For First Psychedelic-Assisted Psychotherapy Clinic

By Vuk Zdinjak

May 5, 8:39 AM

Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) announced that its subsidiary company, Clarion Clinics Group Pty Ltd, has entered a lease for riverfront premises in Abbottsford, Melbourne.

IXHL

2 minute read

Amanita Muscaria Mushrooms Are Taking The Lead In Markets As Research Ramps Up

By Lara Goldstein

May 4, 8:33 AM

Amanita Muscaria is the only kind of mushroom currently legal. As its health benefits are regularly being confirmed in studies, demand for related products is rapidly growing.

PLSH